Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on August 18, 2023. The filing primarily addresses a change in the company's independent registered public accounting firm. The company is incorporated in Florida and its common stock trades on the NYSE American under the symbol OGEN.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures for the current period. However, it references historical financial conditions noted in prior audit reports:
- Going Concern: Previous audit reports by Mayer Hoffman McCann P.C. (MHM) included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
- Cause of Doubt: This doubt was attributed to recurring operating losses, negative operating cash flows, and an accumulated deficit.
- Internal Controls: The company reported that internal control over financial reporting was not effective as of December 31, 2022, due to a material weakness in the review of research and development contracts.
Material Changes
The primary material change reported is the dismissal of the former auditor and the engagement of a new firm:
- Former Auditor: Mayer Hoffman McCann P.C. (MHM) was dismissed effective immediately on August 18, 2023.
- New Auditor: Cherry Bekaert LLP was engaged as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Disagreements: There were no disagreements with MHM regarding accounting principles, practices, or auditing scope during the fiscal years ended December 31, 2022 and 2021, or the interim period through June 30, 2023.
- Restatements: A material weakness in internal controls previously resulted in material errors in unaudited financial statements for Q1, Q2, and Q3 of 2022. These statements were restated and filed with the SEC on April 14, 2023.
Outlook, Risks, and Management Commentary
Management believes the appointment of Cherry Bekaert is in the best interest of shareholders. The company is actively implementing measures to remediate the material weakness in internal controls related to the review of research and development contracts. No consultations were held with Cherry Bekaert regarding accounting principles or audit opinions prior to their engagement. The filing does not contain specific forward-looking guidance or new risk factors beyond the ongoing remediation of internal controls.
Investor Verification Checklist
- Verify the status of the remediation plan for the material weakness in internal controls over financial reporting.
- Review the restated financial statements for Q1, Q2, and Q3 2022 filed on April 14, 2023, to understand the impact of prior errors.
- Monitor upcoming financial reports for updates on the company's liquidity position and recurring operating losses.
- Confirm the execution of the engagement letter with Cherry Bekaert LLP.